R&D Systems Recombinant Human B7-H3 Fc Chimera Protein, CF
Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity
Manufacturer: R&D Systems 1027B3100
DescriptionMeasured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED50 for this effect is 3-12 µg/mL. Optimal dilutions should be determined by each laboratory for each application.
This product(s) resides on a Fisher Scientific GSA or VA contract. If you are viewing this page as a nonregistered user, the price(s) displayed is List Price. To view your GSA or VA contract pricing, log in using your account number, or become a registered user by contacting one of our Customer Service teams. You can also view your contract price by searching for this item(s) on GSA Advantage. To place an order, contact Fisher Scientific Customer Service.
|B7-H3 Fc Chimera|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.|
|<0.10 EU / 1 µg of the protein by the LAL method.|
|Reconstitute at 100 µg/mL in sterile PBS.|
|Lyophilized from a 0.2 µm filtered solution in PBS.|
|M.W. (Observed): 70-80 kDa, reducing conditions; M.W. (theoretical): 50 kDa (monomer)|
|>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.|
|Mouse myeloma cell line, NS0-derived human B7-H3 protein Human B7-H3 (Leu29-Pro245) (N-terminus) Accession # NP_079516 DIEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok